Abstract
Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Current Pharmaceutical Biotechnology
Title: Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Volume: 13 Issue: 1
Author(s): Ying Hu, Graeme H. McIntosh and Graeme P. Young
Affiliation:
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Abstract: Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Export Options
About this article
Cite this article as:
Hu Ying, H. McIntosh Graeme and P. Young Graeme, Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868809
DOI https://dx.doi.org/10.2174/138920112798868809 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Anticancer Activity of 1, 3, 5-Triaryl-1H-Pyrazole
Letters in Drug Design & Discovery The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics in a Global World: A Roadmap for Australia, Prospects and Challenges
Current Pharmacogenomics and Personalized Medicine COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Neuronal Guidance Cues in the Pathophysiology of Obesity: A Peripheral and Central Overview
Current Pharmaceutical Design The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism Potential Health Benefits of Berries
Current Nutrition & Food Science Bioinformatics of Protein-Protein Interfaces and Small Molecule Effectors
Current Bioinformatics Activation of LINE-1 Retrotransposon Increases the Risk of Epithelial-Mesenchymal Transition and Metastasis in Epithelial Cancer
Current Molecular Medicine Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets